$ONC

Ball Titus B. sold $43K of ONC

Ball Titus B. (Principal Accounting Officer) sold 169 shares of BeOne Medicines Ltd. (ONC) at an average of $257.20 ($256.39–$257.53) across 2 trades on 2026-06-11.

Original reporting
SEC EDGAR · Ball Titus B.
Published Jun 15, 2026, 9:55 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 15, 2026, 9:56 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$ONC
Neutral
medium confidence
Mentioned
$ONC
Relevance
3/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ONCNeutralLow
01

Why it matters

This provides a fresh, primary-source datapoint on insider selling activity, but it does not include any new corporate, clinical, or regulatory development.

02

Market read

Traders may monitor for follow-on insider activity, but the disclosure alone is unlikely to drive a sustained repricing without additional catalysts.

03

What to watch

The filing shows the insider ended with 0 shares, but it does not disclose motives, compensation context, or whether other insiders/owners are buying.

Relevance 3/10Novelty 8/10Timing: filed 2026-06-15 for a 2026-06-11 insider sale

Background

The article is an SEC Form 4 insider transaction disclosure for BeOne Medicines Ltd. (ONC).

Company-level read

Ticker impact

$ONCNeutralMedium confidence
Context

BeOne Medicines insider Ball Titus B. sold $43,466.56 of ONC shares via an open-market sale on 2026-06-11, leaving 0 shares.

Expected impact

Likely limited near-term impact; any reaction should fade unless followed by additional disclosures or fundamental news.

Evidence & confidence

The filing is a primary-source insider transaction, but the article provides no new business, guidance, or regulatory/clinical catalyst—only a sale by an accounting officer.

Market effects

Minimal; single insider sale without accompanying company-specific operational updates.

None indicated.

None indicated.

Counterpoint

Insider sales can be planned for liquidity/taxes; the absence of a stated 10b5-1 plan does not necessarily imply negative fundamentals.

Key entities

  • BeOne Medicines Ltd.

    Company whose insider transaction is disclosed on SEC Form 4.

  • Ball Titus B.

    Principal Accounting Officer who sold ONC shares in an open-market transaction.

Related articles

$ONCHigh

BeOne Medicines Ltd. (ONC): Results of Operations and Financial Condition

BeOne Medicines Ltd. (ONC) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 exhibit991-q22026earningsr.htm EX-99.1 Document Exhibit 99.1 BeOne Medicines Announces Second Quarter 2026 Financial Results and Business Updates • Total global revenues of $1.7 billion for the second quarter, an increase of 30% from the prior year • BRUKINSA (zanubruti

$CRCLMed

Here Are Monday’s Best Wall Street Analyst Research Calls: Atmos Energy, Best Buy, Biogen, Capital One, Costco, Disney, Papa John’s International, Shopify, and More

The article lists Monday analyst calls and market moves. It highlights SK hynix’s Nasdaq debut, up about 12.8% to $168.01 after raising nearly $26.5B. It cites upgrades including BIIB to Buy at $235, COF to Buy at $229, and SHOP to Buy at $160, plus downgrades like BBY to Hold. Circle (CRCL) rose ~15% on OCC approval.

$ONCMed

BeOne Medicines (ONC): Citizens Sees an Inflection Point in Its Cancer Pipeline

Citizens kept a “Market Outperform” rating and $396 price target on BeOne Medicines (NASDAQ:ONC) after the company presented tumor clinical data at ASCO 2026. Citizens highlighted three pipeline programs: BGB-43395 (HR+/HER2- metastatic breast cancer), BG-C9074 (ovarian cancer maintenance), and BGB-B2033 (liver cancer). The target was based on discounted earnings and revenue multiples, with Citizens citing $4.85 billion cash and 88% gross margins.